Navigation auf zora.uzh.ch

Search ZORA

ZORA (Zurich Open Repository and Archive)

DDOS: due to massive botnet requests against our ‘Advanced Search’ we have restricted access to UZH (local and VPN). Thank you for your understanding.

Structure-based identification of OATP1B1/3 inhibitors

De Bruyn, Tom; van Westen, Gerard J P; Ijzerman, Adriaan P; Stieger, Bruno; de Witte, Peter; Augustijns, Patrick F; Annaert, Pieter P (2013). Structure-based identification of OATP1B1/3 inhibitors. Molecular Pharmacology, 83(6):1257-1267.

Abstract

Several recent studies show that inhibition of the hepatic transport proteins organic anion-transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3) can result in clinically relevant drug-drug interactions (DDI). To avoid late-stage development drug failures due to OATP1B-mediated DDI, predictive in vitro and in silico methods should be implemented at an early stage of the drug candidate evaluation process. In the present study, we first developed a high-throughput in vitro transporter inhibition assay for the OATP1B subfamily. A total of 2000 compounds were tested as potential modulators of the uptake of the OATP1B substrate sodium fluorescein, in OATP1B1- or 1B3-transfected Chinese hamster ovary cells. At an equimolar substrate-inhibitor concentration of 10 µM, 212 and 139 molecules were identified as OATP1B1 and OATP1B3 inhibitors, respectively (minimum 50% inhibition). For 69 compounds, previously not identified as OATP1B inhibitors, concentration-dependent inhibition was also determined, yielding Ki values ranging from 0.06 to 6.5 µM. Based on these in vitro data, we subsequently developed a proteochemometrics-based in silico model, which predicted OATP1B inhibitors in the test group (20% of the dataset) with high specificity (86%) and sensitivity (78%). Moreover, several physicochemical compound properties and substructures related to OATP1B1/1B3 inhibition or inactivity were identified. Finally, model performance was prospectively verified with a set of 54 compounds not included in the original dataset. This validation indicated that 80 and 74% of the compounds were correctly classified for OATP1B1 and OATP1B3 inhibition, respectively.

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Clinical Pharmacology and Toxicology
08 Research Priority Programs > Integrative Human Physiology
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Life Sciences > Molecular Medicine
Life Sciences > Pharmacology
Language:English
Date:2013
Deposited On:26 Feb 2014 12:56
Last Modified:10 Jun 2025 01:41
Publisher:American Society for Pharmacology and Experimental Therapeutics
ISSN:0026-895X
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1124/mol.112.084152
PubMed ID:23571415

Metadata Export

Statistics

Citations

Dimensions.ai Metrics
107 citations in Web of Science®
118 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 26 Feb 2014
0 downloads since 12 months
Detailed statistics

Authors, Affiliations, Collaborations

Similar Publications